US FDA Classifies Ipca Lab's Silvassa Unit As Voluntary Action
This was after the US FDA's inspection at the manufacturing facility from April 18 to April 26, 2023 that resulted in 3 observations under US FDA Form 483
US FDA Classifies Ipca Lab's Silvassa Unit As Voluntary Action | ipca.com
USFDA has classified Ipca Laboratories Limited's Piparia, Silvassa formulations manufacturing facility as Voluntary Action Induced, the company announced through an exchange filing.
This was after the US FDA's inspection at the manufacturing facility from April 18 to April 26, 2023 that resulted in 3 observations under US FDA Form 483.
Additionally, the regulator has also said that the facility is considered to be in a minimally acceptable state of compliance with regards to the current good manufacturing practice.
Ipca Labs acquires shares in Unichem
Ipca Laboratories earlier this month acquired 2,35,01,440 shares comprising 33.38 per cent of Unichem Laboratories from one of Unichem's promoters. The company bought the shares at a price of ₹402.23 per share aggregating to ₹945.35 crore.
This acquisition is as per the Share Purchase Agreement signed and Public Announcement made on April 24, 2023 and the acquisition of the shares is completed today under block deal mechanism of The National Stock Exchange of India Ltd. (NSE).
Ipca Lab shares
The shares of Ipca Laboratories on Thursday morning at 10:14 am IST were trading at Rs 909.80, up by 3.73 per cent.
RECENT STORIES
-
Godrej Consumer Products Reports 14% Rise In Q2 FY27 Net Profit To ₹523 Crore On Strong Volume... -
Eleven Power To Pursue Legal Remedies After HERC Halts Gurugram, Nuh Distribution Plan -
'Is Your Mom Single?': Fan Seen Holding Placard Asking Ryan Rickelton About His Mother In SA Vs AUS... -
FPJ Quick Take At 5 PM: 'Rahul Gandhi Calls For Delhi March, MCOCA Invoked In Tiger Shroff Firing... -
IndiGo Posts ₹1,879 Crore Net Loss In Q2 FY27 Amid High Fuel Costs, Revenue Up 25.9%
